CytomX emerges from masked obscurity
But now it must show that varseta-M can move into a registrational trial.
Gyre picks up Cullgen for its degraders
Cullgen’s oncology portfolio features TRK, GSPT1 and CDK2 degraders.
Takeda aims at Bristol and Merck
The Japanese group will soon start a trial of its Reblozyl rival in first-line MDS.
ASCO-GU – J&J looks to a pasritamig combo
New data with pasritamig plus docetaxel support a recent pivotal start.
The month ahead: March’s upcoming events
Decisions and readouts loom for the SERDs Astra’s camizestrant and Roche’s giredestrant.
ASCO-GU – Flare hits an “undruggable” target
But biomarker enrichment and toxicity remain key for FX-909.
Rusfertide still needs to be Verified
An FDA verdict is due in the third quarter, as Protagonist looks likely to opt out.
FDA red and green lights: February 2026
The month saw the first commissioner's priority voucher approval in oncology.
Spurned by Sanofi, Orano turns to Roche
The first fruit of a long-standing deal with Roche enters phase 1 in March.
